02:47 PM EDT, 10/16/2024 (MT Newswires) -- Theriva Biologics ( TOVX ) said Wednesday the European Commission has granted orphan medicinal product designation to VCN-01, its lead clinical candidate for the treatment of retinoblastoma.

The company said it is working closely with physicians and regulators globally in refining its clinical strategy for VCN-01 as an adjunct to chemotherapy in children with this type of eye cancer.

Shares of Theriva were up 2.9% in recent trading.

Price: 1.43, Change: +0.04, Percent Change: +2.88